




Expanding Brachytherapy Options Throughout the Body

## UNPARALLELED FIVE-YEAR FREEDOM FROM BIOCHEMICAL FAILURE<sup>1</sup>

Multi-institutional, 100 patient prospective trial demonstrates unequalled biochemical control for low and intermediate risk early stage prostate cancer following brachytherapy alone.<sup>1</sup>



Isotope Dose Delivery Over Time				
Isotope	Half-Life	Energy	90% Dose	Total Dose
Cs-131	9.7 days	30.4 KeV	33 days	115 Gy
Pd-103	17 days	20.8 KeV	58 days	125 Gy
I-125	60 days	28.5 KeV	204 days	145 Gy

1. Prestidge B, Bice W, Moran B, et al. Five-year biochemical control following Cesium-131 permanent prostate brachytherapy in a multi-institutional trial. Brachytherapy 10(3)Suppl. 1: S27-S28, 2011.








Expanding Brachytherapy Options Throughout the Body

Cesium-131

For prostate plans, the relatively high average photon energy of Cs-131 allows the brachytherapy team to achieve excellent prescription dose coverage of the gland while minimizing V150 and other measures of excessive dose.



Rapid resolution of common brachytherapy-related morbidities



Published studies reveal resolution of mild to moderate urinary symptoms beginning at 3 months post Cesium-131 implant<sup>5</sup>, supporting the theoretical argument that dose related side effects dissipate more quickly with shorter-lived isotopes.

1. Yaparpalvi R, Rossinow J, Cavanagh WA, et al. Is Cs-131 or I-125 or Pd-103 the "ideal" isotope for prostate boost brachytherapy? - A dosimetric viewpoint. *Int J Radiat Oncol Biol Phys.* 2007;69(3):S677-678.
2. Bice W, Prestidge B, Jurkovic I, et al. Permanent prostate brachytherapy using Cs-131 for localized prostate carcinoma: a phase II study. Presented at the 2008 Cesium Advisory Group Meeting, November 2008. Tucson, Arizona, U.S.A. 2005.
3. Keyes M, Miller S, Moravan V, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. *Int J Radiat Oncol Biol Phys.* Mar 15 2009;73(4):1023-1032.
4. Ash D, Bottomley D, Al-Qaisieh B, Carey B, Gould K, Henry A. A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. *Radiother Oncol.* Aug 2007;84(2):135-139.
5. Jacobs BL, Smith RP, Beriwal S, Benoit RM. Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131. *Urology.* Nov 2010;76(5):1143-1147.

LUNG · HEAD & NECK · TONSILS · PROSTATE · COLORECTAL · OCULAR MELANOMA · BREAST\* · BRAIN\*

Manufactured and Distributed by IsoRay Medical, Inc.  
350 Hills Street, Suite 106 | Richland, WA 99354  
877.447.6729 | www.IsoRay.com

ADV-045 R3



Cesium-131